Science Explorer Back to mapMap
Discussion
Hospital / health system · Williamsburg · United States

Virginia Oncology Associates

virginiacancer.comROR OpenAlex
Research works
110
▲ 125% vs 2018-21
Citations
4.7k
43.0 per fractional work
Top-10% rate
13.8%
all institutions 10.0%
Open access
24%
world 40%
International
18%
world 18%
Virginia Oncology Associates

Not ranked overall: Virginia Oncology Associates is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Virginia Oncology Associates work in?

In 2022-now, 69% of research at Virginia Oncology Associates is in Health Sciences, 18% in Life Sciences. Its largest fields are Medicine (66%), Biochemistry, Genetics and Molecular Biology (16%), Economics, Econometrics and Finance (8%). It does 2.4× the world's share of Health Sciences.

Health Sciences: 19 fractional works · 69.4% of its workMedicine: 18 fractional works · 65.6% of its workOncology: 7 fractional works · 23.8% of its workPulmonary and Respiratory Medicine: 4 fractional works · 13.2% of its workRadiology, Nuclear Medicine and Imaging: 2 fractional works · 6.7% of its workSurgery: 1 fractional works · 3.2% of its workPublic Health, Environmental and Occupational Health: 1 fractional works · 2.9% of its workPathology and Forensic Medicine: 1 fractional works · 2.3% of its workReproductive Medicine: 1 fractional works · 2.2% of its workHematology: 0 fractional works · 1.4% of its workInfectious Diseases: 0 fractional works · 1.3% of its workEpidemiology: 0 fractional works · 1.2% of its workPhysiology: 0 fractional works · 1.2% of its workObstetrics and Gynecology: 0 fractional works · 1.0% of its workGenetics: 0 fractional works · 0.8% of its workRheumatology: 0 fractional works · 0.8% of its workDermatology: 0 fractional works · 0.8% of its workCardiology and Cardiovascular Medicine: 0 fractional works · 0.6% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 0.5% of its workNeurology: 0 fractional works · 0.4% of its workNephrology: 0 fractional works · 0.3% of its workTransplantation: 0 fractional works · 0.3% of its workFamily Practice: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.4% of its workHealth Professions: 1 fractional works · 3.0% of its workGeneral Health Professions: 1 fractional works · 2.1% of its workEmergency Medical Services: 0 fractional works · 0.9% of its workNursing: 0 fractional works · 0.8% of its workNutrition and Dietetics: 0 fractional works · 0.8% of its workLife Sciences: 5 fractional works · 18.5% of its workBiochemistry, Genetics and Molecular Biology: 4 fractional works · 16.4% of its workCancer Research: 2 fractional works · 7.3% of its workGenetics: 2 fractional works · 5.6% of its workMolecular Biology: 1 fractional works · 3.1% of its workCell Biology: 0 fractional works · 0.3% of its workImmunology and Microbiology: 0 fractional works · 1.8% of its workImmunology: 0 fractional works · 1.8% of its workNeuroscience: 0 fractional works · 0.3% of its workCellular and Molecular Neuroscience: 0 fractional works · 0.3% of its workSocial Sciences: 3 fractional works · 9.7% of its workEconomics, Econometrics and Finance: 2 fractional works · 7.6% of its workEconomics and Econometrics: 2 fractional works · 7.6% of its workSocial Sciences: 1 fractional works · 2.2% of its workGender Studies: 0 fractional works · 1.3% of its workTransportation: 0 fractional works · 0.6% of its workSociology and Political Science: 0 fractional works · 0.3% of its workPhysical Sciences: 1 fractional works · 2.4% of its workEnvironmental Science: 0 fractional works · 1.3% of its workEcology: 0 fractional works · 1.3% of its workEngineering: 0 fractional works · 0.7% of its workBiomedical Engineering: 0 fractional works · 0.4% of its workCivil and Structural Engineering: 0 fractional works · 0.3% of its workComputer Science: 0 fractional works · 0.4% of its workComputer Graphics and Computer-Aided Design: 0 fractional works · 0.4% of its workMaterials Science: 0 fractional works · 0.1% of its workALL ITS WORKVirginia OncologyAssociates27fractional works, 2022-now
Life Sciences18%Physical Sciences2%Health Sciences69%Social Sciences10%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in 2022-now. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 12 fields, with their numbers
    1. Medicine1865.6%
    2. Health Professions13.0%
    3. Nursing00.8%
    1. Biochemistry, Genetics and Molecular Biology416.4%
    2. Immunology and Microbiology01.8%
    3. Neuroscience00.3%
    1. Economics, Econometrics and Finance27.6%
    2. Social Sciences12.2%
    1. Environmental Science01.3%
    2. Engineering00.7%
    3. Computer Science00.4%
    4. Materials Science00.1%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 3.08× its world share, 4 worksBiochemistry, Geneti…Immunology and Microbiology: 1.79× its world share, 0 worksImmunology and Micro…Neuroscience: 0.15× its world share, 0 worksNeuroscienceComputer Science: 0.05× its world share, 0 worksComputer ScienceEngineering: 0.04× its world share, 0 worksEngineeringEnvironmental Science: 0.26× its world share, 0 worksEnvironmental ScienceMaterials Science: 0.02× its world share, 0 worksMaterials ScienceHealth Professions: 1.15× its world share, 1 worksHealth ProfessionsMedicine: 3.41× its world share, 18 worksMedicineNursing: 1.60× its world share, 0 worksNursingEconomics, Econometrics and Finance: 3.54× its world share, 2 worksEconomics, Econometr…Social Sciences: 0.17× its world share, 1 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Economics, Econometrics and Finance, 3.5×. Every wedge is a field page.

All 12 fields, with their numbers
  1. Economics, Econometrics and Finance3.54×2 works
  2. Medicine3.41×18 works
  3. Biochemistry, Genetics and Molecular Biology3.08×4 works
  4. Immunology and Microbiology1.79×0 works
  5. Nursing1.60×0 works
  6. Health Professions1.15×1 works
  7. Environmental Science0.26×0 works
  8. Social Sciences0.17×1 works
  9. Neuroscience0.15×0 works
  10. Computer Science0.05×0 works
  11. Engineering0.04×0 works
  12. Materials Science0.02×0 works

Who are the top researchers at Virginia Oncology Associates?

Ranked on the quality score, Mark T. Fleming, Michael A. Danso and Daniel M. Atienza lead among researchers whose main affiliation is Virginia Oncology Associates.

  1. 1 Mark T. Fleming United States · #131,257 worldwide 16k citations · 213 works
  2. 2 Michael A. Danso United States · #167,551 worldwide 4.8k citations · 121 works
  3. 3 Daniel M. Atienza United States · #641,709 worldwide 1.4k citations · 24 works
  4. 4 Joseph J. Muscato United States · #958,711 worldwide 1.1k citations · 19 works
  5. 5 Paul Conkling United States · #1,265,562 worldwide 4.1k citations · 140 works
  6. 6 Ranjit K. Goudar United States · #2,062,819 worldwide 941 citations · 23 works
  7. 7 Michael E. McCollum United States · #2,703,936 worldwide 888 citations · 16 works
All ranked researchers at Virginia Oncology Associates

What are the most cited papers from Virginia Oncology Associates?

The most cited paper from Virginia Oncology Associates is "Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy" (Howard I. Scher, Karim S. Fizazi, Fred Saad et al., 2012), with 4,645 citations. Next come "Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial" (3,762) and "Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials" (1,802).

Most cited papers
#PaperReleasedCitations
1 Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy Howard I. Scher, Karim S. Fizazi, Fred Saad et al. · New England Journal of Medicine Open access 15 Aug 2012 4,645
2 Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Jonathan E. Rosenberg et al. · The Lancet Open access 5 Mar 2016 3,762
3 Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials Robert Charles Doebele et al. · The Lancet Oncology Open access 11 Dec 2019 1,802
4 Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma Yohann Loriot et al. · New England Journal of Medicine Open access 24 Jul 2019 1,396
5 Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial Fairooz F. Kabbinavar, Joseph J. Schulz, Michael McCleod et al. · Journal of Clinical Oncology Open access 28 Feb 2005 936
All 60 most cited papers, with filters and sorting

Which keywords describe research at Virginia Oncology Associates?

By fractional works in 2022-now, weighted toward what it does more of than the world: Breast Cancer, Immunotherapy, Metastatic Breast Cancer, Chemotherapy, Radiotherapy, Clinical Trials, Cost of Care and Financial Toxicity.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in 2022-now in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 36 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 36 words, with their numbers
  1. Breast Cancer3▲ 50×6 topics
  2. Immunotherapy3▲ 15×8 topics
  3. Metastatic Breast Cancer3▲ 177×2 topics
  4. Chemotherapy3▲ 13×12 topics
  5. Radiotherapy2▲ 21×7 topics
  6. Clinical Trials2▲ 12×6 topics
  7. Cost of Care2▲ 240×1 topic
  8. Financial Toxicity2▲ 240×1 topic
  9. Prognostic Factors2▲ 15×10 topics
  10. Targeted Therapy2▲ 30×4 topics
  11. Clinical Practice Guidelines2▲ 12×7 topics
  12. Quality of Life2▲ 4.3×3 topics
  13. Chemotherapy-Induced Peripheral Neuropathy2▲ 178×1 topic
  14. Gene Expression2▲ 8.9×5 topics
  15. Molecular Subtypes2▲ 61×3 topics
  16. Taxanes2▲ 178×1 topic
  17. Biomarkers1▲ 7.2×3 topics
  18. CDK4/6 Inhibitors1▲ 175×1 topic
  19. Cell Cycle Control1▲ 152×2 topics
  20. Neoadjuvant Therapy1▲ 21×3 topics
  21. Palbociclib1▲ 175×1 topic
  22. Lymphoma1▲ 31×2 topics
  23. Metastatic1▲ 73×2 topics
  24. Prognostic Markers1▲ 42×2 topics
  25. Survival Analysis1▲ 18×6 topics
  26. Tumor Microenvironment1▲ 11×5 topics
  27. Breast Tumours1▲ 88×1 topic
  28. Cancer1▲ 3.2×13 topics
  29. Cancer Treatment1▲ 19×4 topics
  30. Treatment Response1▲ 88×1 topic
  31. Immune Checkpoint Blockade1▲ 36×1 topic
  32. PD-1 and PD-L11▲ 36×1 topic
  33. Treatment1▲ 3.2×6 topics
  34. Cancer Immunotherapy1▲ 25×3 topics
  35. Epidemiology1◆ 0.94×10 topics
  36. Genetic Mutations1▲ 8.6×4 topics

Which research topics does Virginia Oncology Associates publish most on?

By volume in 2022-now: Economic and Financial Impacts of Cancer, Cancer Treatment and Pharmacology, Advanced Breast Cancer Therapies and Breast Cancer Treatment Studies.

Economic and Financial I…2Economic and Financial Impacts of Cancer: 2 fractional worksCancer Treatment and Pha…2Cancer Treatment and Pharmacology: 2 fractional worksAdvanced Breast Cancer T…1Advanced Breast Cancer Therapies: 1 fractional worksBreast Cancer Treatment …1Breast Cancer Treatment Studies: 1 fractional worksCancer Immunotherapy and Biomarkers: 1 fractional worksCAR-T cell therapy research: 1 fractional worksHER2/EGFR in Cancer Rese…1HER2/EGFR in Cancer Research: 1 fractional worksAdvances in Oncology and Radiotherapy: 1 fractional worksCancer Genomics and Diagnostics: 1 fractional worksProstate Cancer Treatment and Research: 1 fractional works
Economics and EconometricsOncologyPulmonary and Respiratory MedicineCancer Research1 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Economic and Financial Impacts of Cancer Economics and Econometrics 2 works
  2. 2 Cancer Treatment and Pharmacology Oncology 2 works
  3. 3 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 1 works
  4. 4 Breast Cancer Treatment Studies Cancer Research 1 works
  5. 5 Cancer Immunotherapy and Biomarkers Oncology 1 works
  6. 6 CAR-T cell therapy research Oncology 1 works
  7. 7 HER2/EGFR in Cancer Research Oncology 1 works
  8. 8 Advances in Oncology and Radiotherapy Radiology, Nuclear Medicine and Imaging 1 works
  9. 9 Cancer Genomics and Diagnostics Cancer Research 1 works
  10. 10 Prostate Cancer Treatment and Research Pulmonary and Respiratory Medicine 1 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available24.2%not open75.8%

World: 40% of research is openly available.

with international co-authors18.4%domestic only81.6%

World: 18% is written across borders.

How has Virginia Oncology Associates's research output changed?

Output in 2022-2025 was 125% higher than in 2018-2021.

still counting1990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Virginia Oncology Associates as a percentage of every work published that year, 0.00011% in 2024.

still counting0.00050%0.0010%Virginia Oncology Associates0.00011% in 202519801990200020102020

Fractional works of Virginia Oncology Associates over all fractional works that year. How the balance of science has shifted.

Other research institutions in Williamsburg

All research institutions in Williamsburg

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Virginia Oncology Associates. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.